West Pharmaceutical Defies Doubters: EPS Jumps, Outlook Raised Despite Tariff Drag

West Pharmaceutical topped Q1 estimates and raised 2025 guidance, citing stronger device demand and improved inventory trends across key markets.

Latest Ratings for WST

DateFirmActionFromTo Jul 2021KeybancMaintainsOverweight Nov 2020KeybancInitiates Coverage OnOverweight Oct 2020Stephens & Co.Initiates Coverage OnEqual-Weight

View More Analyst Ratings for WST

View the Latest Analyst Ratings

read more